| Identification | Back Directory | [Name]
T 0632 | [CAS]
169042-78-8 | [Synonyms]
T 0632
3-[(3S)-1-(2-fluorophenyl)-6-methoxy-2-oxo-3-(1,2,3,4-tetrahydronaphthalene-2-carbonylamino)indol-3-yl]propanoic acid | [Molecular Formula]
C28H23FN3NaO5 | [MDL Number]
MFCD27976885 | [MOL File]
169042-78-8.mol | [Molecular Weight]
523.5 |
| Hazard Information | Back Directory | [Description]
T-0632 is a novel potent and selective CCKA receptor antagonist. | [Uses]
T-0632 is a CCK A receptor antagonist that exhibits significant pharmacological properties in in vitro studies. T-0632 competitively inhibits the binding of [125I]CCK-8 to rat pancreatic CCK A receptors with a K_i value of 0.24 nM, which is significantly lower than the K_i value for guinea pig CCK B receptors. T-0632 has higher selectivity in inhibiting CCK-8-stimulated pancreatic enzyme release, with an IC_50 value of 5.0 nM, which is more advantageous than L-364,718 and loxiglumide. In rabbit gallbladder smooth muscle, the antagonistic effects of T-0632 and loxiglumide are reversible, while L-364,718 shows a persistent inhibitory effect. These results indicate that T-0632 is a highly potent, reversible and more selective CCK A receptor antagonist. | [References]
[1] Pharmacological profile of T-0632, a novel potent and selective CCK A receptor antagonist, in vitro |
|
|